SLC12A5 and prostate adenocarcinoma: Then, the Kaplan-Meier survival methods were further utilized to assess the prognostic impact of SLC12A5 in human cancers, and as revealed in Figures 3(a)–3(d), high SLC12A5 expression was distinctly associated with shorter overall survival of patients with KIRC, LAML, UCEC, and PRAD, whereas the lower the SLC12A5 expression level, the worse the OS of PAAD (Figure 3(e)).